Cellspan oesophageal implant - Biostage

Drug Profile

Cellspan oesophageal implant - Biostage

Alternative Names: Cellspan Paediatric Oesophageal Implant - Biostage; Oesophageal stem cell implant - Biostage

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biostage
  • Class Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal atresia; Oesophageal cancer
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Oesophageal cancer

Most Recent Events

  • 11 Sep 2017 Biostage plans a phase I trial for Oesophageal atresia in USA in 4Q 2017
  • 14 Aug 2017 Clinical trials in Oesophageal cancer in USA (Implant)
  • 14 Aug 2017 Biostage plans a clinical trial for Oesophageal atresia in paediatrics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top